Monoclonal antibodies (mAbs) are one of the robust classes of therapeutic proteins. Their stability, specificity, and high solubility allow the successful development and commercialization of antibody-based drugs. Though with these characteristics, mAbs projects are often suspended due to self- or cross-interaction of monoclonal antibodies. This is one of the main reasons which causes the development of mAbs into drugs taking forever and expensive. CISI is short for cross-interaction or self-interaction of mAbs. It can be quantified by several assays. The assays such as poly-specificity reagent and cross-interaction chromatography can measure cross-interaction of mAbs. Self-interaction can be assayed through clone self-interaction by biolayer interferometry and affinity-capture self-interaction nanoparticle spectroscopy. To save time and money, we developed a model called CISI which can predict cross-interaction or self-interaction based on tripeptide composition. It showed 88.20% accuracy, 90.22% sensitivity, 86.05% specificity, 0.78 Mathew correlation coefficient, and 0.96 area under the receiver operating characteristic (ROC) curve (AUC) in the leave-one-out cross-validation. CISI is freely available at http://i.uestc.edu.cn/eli/cgi-bin/cisi.pl.

中文翻译：

---

CISI：一种使用序列预测单克隆抗体的交叉相互作用或自相互作用的工具。

单克隆抗体（mAb）是治疗性蛋白质的强大类别之一。它们的稳定性，特异性和高溶解度使基于抗体的药物得以成功开发和商业化。尽管具有这些特征，但由于单克隆抗体的自身相互作用或交叉相互作用，mAbs工程常常被暂停。这是导致单克隆抗体发展成为永久且昂贵的药物的主要原因之一。CISI是单克隆抗体的交叉相互作用或自相互作用的缩写。可以通过几种测定来量化。诸如多特异性试剂和交叉相互作用色谱之类的测定法可以测量mAb的交叉相互作用。可以通过生物层干涉法和亲和捕获自相互作用纳米粒子光谱学通过克隆自相互作用来测定自相互作用。为了节省时间和金钱，我们开发了一种称为CISI的模型，该模型可以根据三肽组成预测交叉相互作用或自我相互作用。在留一法交叉验证中，它在接收器工作特征（ROC）曲线（AUC）下显示了88.20％的准确度，90.22％的灵敏度，86.05％的特异性，0.78的马修相关系数和0.96的面积。CISI可从http://i.uestc.edu.cn/eli/cgi-bin/cisi.pl免费获得。